openPR Logo
Press release

Leukemia Cancer Market Share 2023: Trends, Key Players, Industry Analysis and Forecast 2023-2029

02-16-2023 12:58 PM CET | Health & Medicine

Press release from: Orion Market Research

Leukemia Cancer Market Share 2023: Trends, Key Players,

The global leukemia cancer market is anticipated to grow at a considerable CAGR of 5.1% during the forecast period. Increasing investments in the healthcare sector and the rising development of new drugs and therapeutics will drive the market in the forecast period. According to WHO, globally leukemia cancer is considered to be the most common blood cancer. Thus, to treat and cure rising incidences of cancer across the globe, drug manufacturers and market players are conducting several R&D activities. For instance, in March 2022, Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage pharmaceutical company focused on R&D for novel cancer therapeutics, today announced that the first patient has been dosed in the Phase 1/2 study of DSP-5336, an inhibitor of melanin binding to mixed-lineage leukemia (MLL) protein, in patients with relapsed or refractory acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL).

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/leukemia-cancer-market

In September 2021, Intas Pharmaceuticals Ltd announced the launch of Azadine-O, an oral Azacitidine therapy for Acute Myeloid Leukemia (a type of blood cancer), a first for the Indian market. Oral Azacitidine is approved for use in maintenance therapy for adult patients with Acute Myeloid Leukaemia. It can improve survival by almost 10 months and bridge a long-pending unmet need in cancer therapy.

Further, in December 2020, Jazz Pharmaceuticals plc announced that the company has initiated the submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) seeking marketing approval for JZP-458 for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in adult and pediatric patients who have developed hypersensitivity or silent inactivation to E. coli-derived asparaginase.

Market Coverage

• The market number available for - 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Type
o By Diagnose & Monitor
o By Treatment
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- including Bristol-Myers Squibb, Celgene Corp., Daiichi Sankyo Co., Ltd., F. Hoffmann-La Roche Ltd., and others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Leukemia Cancer Market Report Segment

By Type

• Acute Myeloid Leukemia (AML)
• Chronic Myeloid Leukemia (CML)
• Acute Lymphoblastic Leukemia (ALL)
• Chronic Lymphocytic Leukemia (CLL)

By Diagnose & Monitor

• Blood Test
• Bone Marrow Test
• Imaging Test
• Lymph Node Biopsy
• Lumbar Puncture
• Urine Test

By Treatment

• Chemotherapy
• Radiation Therapy
• Targeted Therapy
• Biological Therapy
• Stem Cell Therapy

A full report of Leukemia Cancer Market is available at: https://www.omrglobal.com/industry-reports/leukemia-cancer-market

Leukemia Cancer Market- Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• Actinium Pharmaceuticals Inc.
• Biogen Idec Inc.
• Bristol-Myers Squibb
• Celgene Corp. (Bristol-Myers Squibb)
• Daiichi Sankyo Co., Ltd.
• Eisai Co. Ltd.
• Epizyme Inc.
• Erytech Pharma S.A.
• F. Hoffmann-La Roche Ltd.
• Genmab A/S
• Glaxosmithkline Plc
• Novartis International AG
• Pfizer Inc.
• Sanofi

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

Visit More Report at

https://www.asiatimeskorea.com/press-release/%eb%b0%b1%ed%98%88%eb%b3%91-%ec%95%94-%ec%8b%9c%ec%9e%a5-%eb%8f%99%ed%96%a5-%eb%b6%84%ed%95%a0-%ec%84%b1%ec%9e%a5-%eb%b6%84%ec%84%9d-%eb%b0%8f-%ec%98%88%ec%b8%a1-2023-2029/328630/

https://www.diario-ya.com/regionales/2023-2029-%e5%b9%b4%e5%9f%b9%e5%85%bb%e5%9f%ba%e3%80%81%e8%a1%80%e6%b8%85%e5%92%8c%e8%af%95%e5%89%82%e5%b8%82%e5%9c%ba%e4%bb%bd%e9%a2%9d%e3%80%81%e8%b6%8b%e5%8a%bf%e3%80%81%e5%88%86%e6%9e%90%e5%92%8c/392206/

https://sportmsr.com/2029-%d8%a7%d8%aa%d8%ac%d8%a7%d9%87%d8%a7%d8%aa-%d8%b3%d9%88%d9%82-%d8%a7%d9%84%d9%85%d8%ad%d8%a7%d9%83%d8%a7%d8%a9-%d8%a7%d9%84%d8%b7%d8%a8%d9%8a%d8%a9-%d8%8c-%d8%a7%d9%84%d8%aa%d8%ac%d8%b2%d8%a6/

https://monblogapple.com/2023/02/11/taille-part-croissance-analyse-et-previsions-du-marche-de-la-technologie-de-separation-membranaire-2023-2029/

https://citytoday-hildesheim.de/index.php/2023/02/11/micro-guide-catheter-marktgrose-marktanteil-beeindruckendes-branchenwachstum-analysebericht-2029/

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Leukemia Cancer Market Share 2023: Trends, Key Players, Industry Analysis and Forecast 2023-2029 here

News-ID: 2933718 • Views:

More Releases from Orion Market Research

European Augmented Reality Market Size 2024: Global Share, Industry And Report Analysis By 2031 | Rokid Corp. Ltd. Seiko Epson Corp. Thales Group
European Augmented Reality Market Size 2024: Global Share, Industry And Report A …
European augmented reality market is estimated to grow significantly at a CAGR of more than 36.5% during the forecast period. European Augmented Reality Market research report allows making important decision making essential for business growth. It helps key participants further in applying right business ideas to grow business and choose the right business doing strategy. Having complete understanding of what purchasers are looking for in the market and which factors
Germany Augmented Reality Market Size 2024: Global Share, Industry And Report Analysis By 2031 | Rokid Corp. Ltd. Seiko Epson Corp. Thales Group
Germany Augmented Reality Market Size 2024: Global Share, Industry And Report An …
Germany augmented reality market is estimated to grow significantly at a CAGR of more than 34% during the forecast period. This informative Germany Augmented Reality Market report provides new method and covers foremost regions such as Latin America, Middle East, North America, Europe, Africa and Asia Pacific. Making most out of the consumer insights and market opportunities, market players can boost up the revenue rate of their business. It also
North American Augmented Reality Market Size 2024: Global Share, Industry And Report Analysis By 2031 | Rokid Corp. Ltd. Seiko Epson Corp. Thales Group
North American Augmented Reality Market Size 2024: Global Share, Industry And Re …
North American augmented reality market is estimated to grow significantly at a CAGR of 36.8% during the forecast period. This North American Augmented Reality Market research report focuses more on a number of distinctive as well as foremost market sectors. It further focuses market segmentation. Industry-specific interviews are carried out with market players to foresee future business growth. Various facets of the industry are also depicted here under each industry
UK Augmented Reality Market Size 2024: Global Share, Industry And Report Analysis By 2031 | NXP Semiconductors NV Scheidt & Bachmann GmbH Smartrac Technology GmbH
UK Augmented Reality Market Size 2024: Global Share, Industry And Report Analysi …
UK augmented reality market is estimated to grow significantly at a CAGR of 36.5% during the forecast period. This UK Augmented Reality Market research report focuses more on a number of distinctive as well as foremost market sectors. It further focuses market segmentation. Industry-specific interviews are carried out with market players to foresee future business growth. Various facets of the industry are also depicted here under each industry sector. Future

All 5 Releases


More Releases for Leukemia

Pipeline Review, H2 2017 of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic …
"Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2017" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. . . Description- '
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, T …
Orbisreserach.Com Adds “H1 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Market Pipeline Review 2017 Trend Analysis Report Report” To Its Research Database Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2017, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape. Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the
Acute Lymphoblastic Leukemia (ALL) Market grows with high incidence of acute lym …
Acute lymphoblastic leukemia (ALL) is a cancer of white blood cells called as lymphocytes in bone marrow. It is a malignant disease in which early precursor lymphoid cells proliferate and replace the normal hematopoietic cells of bone marrow. ALL is the most common type of cancer in children. There is overproduction of lymphoblasts in the bone marrow when a person suffers from ALL that continuously multiply, damaging the bone marrow
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical T …
ReportsWorldwide has announced the addition of a new report title Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Tri …
ReportsWorldwide has announced the addition of a new report title Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to
H2 2016 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeut …
Albany, New York, January 03, 2017: A recent forecast report focusing on the Acute Myelocytic Leukemia Market has been added to the wide portfolio of Market Research Hub (MRH). It is entitled as, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016” which has been equipped by in-depth market examination with inputs from the industry experts. It covers the current market scenario and also its future growth